ClinicalTrials.gg
CompletedNCT06727058Updated Apr 23, 2026

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

A Phase 1/2 interventional study of Pandemic flu H5 mRNA vaccine and Placebo in Influenza Immunization, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 14 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 139 studies in Influenza, Human by Sanofi — 4 open to participants now, 6 under way, 1 of them phase 3. Influenza, Human · Sanofi.

Enrollment
70th of 126
276 · median 305
Started
2024
with 7 others
Phase 1/2
13 of 139
1 open now
Registered
130th of 139
by date

Among the 139 studies in Influenza, Human by Sanofi, this one is the 70th largest by enrollment of the 126 interventional ones that give a count, is one of 8 that started in 2024, is one of 13 in phase 1/2, and was the 130th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 139 studies in Influenza, Human by Sanofi are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Influenza, Human by Sanofi, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate a pandemic flu H5 strain messenger ribonucleic acid (mRNA) vaccine at 3 dose levels (low, medium, and high) in comparison with placebo in 276 healthy adult participants to select the adequate dose for further clinical development.

The duration per participant will be approximately 13 months.

03

Conditions studied

  • Influenza Immunization

Browse trials for

Keywords

  • pandemic influenza infection
  • H5 strain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older on the day of inclusion.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

    • Is of non-. To be considered of non-childbearing potential, a female must be for at least 1 year, or surgically sterile.

OR

  • Is of childbearing potential and agrees to use an effective method or abstinence from at least 4 weeks prior to each study intervention administration until at least 12 weeks after the last study intervention administration.
  • A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours before the first dose of study intervention.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • Known systemic to any of the study intervention components (eg, polyethylene glycol, polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of an mRNA vaccine .
  • Previous history of myocarditis, pericarditis, and/or myopericarditis.
  • Known history of previous episodes of Guillain-Barré Syndrome (GBS), neuritis (including Bell's palsy), convulsions , encephalitis, transverse myelitis, and vasculitis.
  • Participants with an that is consistent with possible myocarditis or pericarditis or, in the opinion of the investigator, demonstrates abnormalities that may affect participant safety or study results.
  • Self-reported thrombocytopenia, contraindicating IM injection based on investigator's judgment.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM injection based on investigator's judgment.
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion.
  • Moderate or severe acute illness / infection (according to investigator's judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the investigator, might interfere with the study conduct or completion.
  • Participant who had acute infectious symptoms or a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcriptase polymerase chain reaction (RT PCR) or antigen test in the past 10 days prior to the first visit (V)01.
  • Receipt of any vaccine other than an mRNA vaccine in the 4 weeks preceding study intervention administration or planned receipt of any vaccine other than an mRNA vaccine in the 3 weeks following the second dose of the study intervention .
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Receipt of any mRNA vaccine/product in the 2 months preceding study intervention administration or planned receipt of any mRNA vaccine in the 2 months after the second dose of the study intervention.
  • Participation at the time of study enrollment (or in the 4 weeks preceding study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.
  • Previous history of participation in an H5 influenza A vaccine study. This includes any influenza subtypes that contain H5 such as H5N1, H5N8, or H5N6.

Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
276 participants (actual)

Study arms

  • Experimental
    Group 1: Low Dose Pandemic flu H5 mRNA vaccine

    Participants will receive 2 injections of pandemic flu H5 mRNA vaccine 21 days apart (at Day 01 and Day 22)

    Biological: Pandemic flu H5 mRNA vaccine

  • Experimental
    Group 2: Medium Dose Pandemic flu H5 mRNA vaccine

    Participants will receive 2 injections of pandemic flu H5 mRNA vaccine 21 days apart (at Day 01 and Day 22)

    Biological: Pandemic flu H5 mRNA vaccine

  • Experimental
    Group 3: High Dose Pandemic flu H5 mRNA vaccine

    Participants will receive 2 injections of pandemic flu H5 mRNA vaccine 21 days apart (at Day 01 and Day 22)

    Biological: Pandemic flu H5 mRNA vaccine

  • Placebo comparator
    Group 4: Placebo

    Participants will receive 2 injections of placebo 21 days apart (at Day 01 and Day 22)

    Other: Placebo

Interventions

  • BiologicalPandemic flu H5 mRNA vaccine

    Pharmaceutical Form: Suspension for injection Route of Administration: Intramuscular (IM)

  • OtherPlacebo

    Pharmaceutical Form: Liquid solution for injection Route of Administration: Intramuscular (IM)

06

What researchers measure

Primary outcomes

  1. Presence of immediate adverse events (AEs) within 30 minutes after each/any injection

    Number of participants experiencing immediate AEs

    Time frame: Within 30 minutes of any/each injections

  2. Presence of solicited injection site reactions through 7 days after each/any injection

    Number of participants experiencing solicited injection site reactions

    Time frame: Through 7 days after each/any injections

  3. Presence of solicited systemic site reactions through 7 days after each/any injection

    Number of participants experiencing solicited systemic site reactions

    Time frame: Through 7 days after each/any injections

  4. Presence of unsolicited AEs through 21 days after the first injection and through 28 days after the second injection

    Number of participants experiencing unsolicited AEs

    Time frame: Through 21 days after the first injection and through 28 days after the second injection

  5. Presence of medically attended adverse events (MAAEs) through 180 days after the last injection

    Number of participants experiencing MAAEs

    Time frame: Through 180 days after the last injection

  6. Presence of adverse events of special interest (AESIs) throughout the study

    Number of participants experiencing AESIs

    Time frame: Throughout the study, approximately 13 months

  7. Presence of serious adverse events (SAEs) throughout the study

    Number of participants experiencing SAEs

    Time frame: Throughout the study, approximately 13 months

  8. Presence of out-of-range biological test results (including shift from baseline values) through a maximum of 8 days after each injection

    Number of participants with out-of-range biological test results

    Time frame: Through a maximum of 8 days after each injection

Secondary outcomes

  1. Antibody titers measured by Hemagglutination Inhibition (HAI) Assay

    Antibody titers are expressed as geometric mean titers (GMTs)

    Time frame: At Day 01, Day 22, Day 43, Day 112, and Day 202

  2. Individual HAI titer ratio

    Time frame: At Day 22/Day 01, Day 43/Day 01, Day 112/Day 01, and Day 202/Day 01

  3. ≥ 4-fold increase in HAI titer [1/dilution])

    Time frame: At Day 22 or Day 43

  4. HAI titer ≥ 10 [1/dilution]

    Time frame: At day 01

  5. HAI titer ≥ 40 [1/dilution]

    Time frame: At Day 01, Day 22, Day 43, Day 112, and Day 202

  6. Detectable HAI titer ≥ 10 [1/dilution]

    Time frame: At Day 01, Day 22, Day 43, Day 112, and Day 202

  7. Antibody titers measured by Seroneutralization (SN) test

    Antibody titers are expressed as GMTs

    Time frame: At Day 01, Day 22, Day 43, Day 112, and Day 202

  8. Individual SN titer ratio

    Time frame: Day 22/Day 01, Day 43/Day 01, Day 112/Day 01, and Day 202/Day 01

  9. SN titer ≥ 20 (1/dilution)

    Time frame: At Day 01, Day 22, Day 43, Day 112, and Day 202

  10. SN titer ≥ 40 (1/dilution)

    Time frame: At Day 01, Day 22, Day 43, Day 112, and Day 202

  11. SN titer ≥ 80 (1/dilution)

    Time frame: At Day 01, Day 22, Day 43, Day 112, and Day 202

  12. Detectable SN titer ≥ 10 (1/dilution)

    Time frame: At Day 01, Day 22, Day 43, Day 112, and Day 202

  13. 2-fold rise in SN titer

    Time frame: At Day 22 and Day 43

  14. 4-fold rise in SN titer

    Time frame: At Day 22 and Day 43

07

Study locations

14 sites
  • Velocity Clinical Research - San Diego- Site Number : 8400013
    La Mesa, California 91942, United States
  • Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400002
    DeLand, Florida 32720, United States
  • ARSN-Lakeland CRU- Site Number : 8400006
    Lakeland, Florida 33803, United States
  • Accel Research Sites - St. Petersburg- Site Number : 8400004
    Largo, Florida 33777, United States
  • Atlanta Clinical Research Center- Site Number : 8400007
    Atlanta, Georgia 30342, United States
  • Accel Research Site - NeuroStudies.net, LLC - ERN - PPDS- Site Number : 8400003
    Decatur, Georgia 30030-2627, United States
  • QUEST Research Institute- Site Number : 8400014
    Bingham Farms, Michigan 48334, United States
  • Velocity Clinical Research - Norfolk- Site Number : 8400015
    Norfolk, Nebraska 68701, United States
  • Velocity Clinical Research - Omaha- Site Number : 8400012
    Omaha, Nebraska 68134, United States
  • Velocity Clinical Research - Springdale- Site Number : 8400010
    Cincinnati, Ohio 45246, United States
  • Coastal Carolina Research Center - North Charleston- Site Number : 8400001
    North Charleston, South Carolina 29405, United States
  • Olympus Clinical Research - Sugar Land- Site Number : 8400009
    Sugar Land, Texas 77479, United States
  • Velocity Clinical Research, Salt Lake City- Site Number : 8400011
    West Jordan, Utah 84088, United States
  • Charlottesville Medical Research- Site Number : 8400005
    Charlottesville, Virginia 22911, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Mar 2026, 15 months.

Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 15 months is above that.

Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2024
First posted
Dec 10, 2024
StartActual
Dec 9, 2024
Primary completionActual
Mar 24, 2026
CompletionActual
Mar 24, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06727058
Responsible party
Sponsor
First posted
Dec 10, 2024
Start date
Dec 9, 2024
Primary completion
Mar 24, 2026
Completion
Mar 24, 2026
Last update
Apr 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion